Literature DB >> 17147920

Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States?

Ralph G Hawkins1.   

Abstract

In the quest for "evidence-based" medicine, an accepted hierarchy of evidence has been proposed. This hierarchy places in vitro studies and animal data at the base, and puts systematic reviews, meta-analyses, and randomized controlled trials at the pinnacle. However, when clinical medicine faces questions that have not yet been studied by the "gold standard" methods, how is one to proceed? Often, the best evidence at hand falls short of randomized controlled trials and meta-analyses. Using this framework, a review of the evidence supporting the hypothesis that population-wide diuretic use is directly associated with end-stage renal disease in the United States is presented. Publications pertaining to diuretic use in recent clinical trials are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17147920     DOI: 10.1007/s11906-006-0054-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  38 in total

1.  Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies.

Authors:  Bruce M Psaty; Thomas Lumley; Curt D Furberg
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Preferences and practices of Americans and their physicians in antihypertensive therapy.

Authors:  G Gallup; H E Cotugno
Journal:  Am J Med       Date:  1986-12-31       Impact factor: 4.965

4.  Increasing incidence of end-stage renal disease in Wisconsin: an unintended consequence of increased survival?

Authors:  A Russell; P Remington; D D'Alessio; P Brazy
Journal:  WMJ       Date:  2001

Review 5.  The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle.

Authors:  L Goldman; E F Cook
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

Review 6.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

7.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

8.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

9.  Captopril, aldosterone and urinary kallikrein in primary hypertension.

Authors:  K P Ohman; B E Karlberg; O R Nilsson; S Wettre
Journal:  Clin Exp Hypertens A       Date:  1983

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  1 in total

Review 1.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.